Company Press Release
Source: Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. Announces Key Promotions
NEW HAVEN, Conn., May 12 /PRNewswire/ -- Vion Pharmaceuticals, Inc. (Nasdaq:VION) today announced the promotions of seven senior level executives and senior scientists at the Company. These promotions are effective immediately.
Bijan Almassian, Ph.D. has been appointed to the position of Vice President of Development. Prior to this promotion, Dr. Almassian was Director of Development at Vion, a position he has held for one and a half years. Before joining Vion, Dr. Almassian was Director of Pharmaceutical Development at Genelebs, Inc. Dr. Almassian earned his Ph.D. from Massachusetts College of Pharmacy in Boston and his M.S. from Northeastern University.
Ellen Carmichael, Ph.D has been appointed Associate Director of Strategic & Corporate Development. Previously, Dr. Carmichael was Associate Director of Biology at Vion where she specialized in virology. Prior to joining Vion, Dr. Carmichael was a Senior Scientst at TargeTech, Inc. Dr. Carmichael received her Ph.D. from the University of Connecticut and her B.S. from Fairfield University.
Ivan King, Ph.D. has been promoted to Senior Director of Biology at Vion. In his new position, Dr. Kinwill continue to lead Vion's biology team in their research and development efforts. Previously, Dr. King was Section Leader for Tumor Biology at Schering-Plough Research Institute. Dr. King earned his Ph.D. from University of Texas Health Science Center in Houston and his M.Ph. degree from The Chinese University of Hong Kong.
``I thank each one of these individuals and attribute many of Vion's accomplishments to their unfailing energy, brilliance and commitment. With the continued expansion of our research and development programs these individuals will be key to the Company's future success and growth,'' said John Spears, President and CEO of Vion.
David Bermudes, Ph.D has been appointed Associate Director of Biology. Previously, Dr. Bermudes was a Senior Research Scientist at Vion, where he was principally involved in the development of TAPET(TM), the Company's gene therapy for cancer technology. Prior to joining Vion, Dr. Bermudes was Associate Research Scientist at Yale University School of Medicine. Dr. Bermudes received his Ph.D. and M.A. from Boston University and his B.A. from Oberlin College.
Stanley Lin, Ph.D. has been named Associate Director of Biology. Most recently, Dr. Lin was Biology Group Leader where he was involved in the development of TAPET. He was previously in the Tumor Biology group at Schering-Plough Research Institute. Dr. Lin received his Ph.D. and B.A. from Johns Hopkins University.
Li-mou Zheng, Ph.D. has been named Associate Director of Biology. Formerly Biology Group Leader, Dr. Zheng contributed to the development of TAPET. Before joining Vion, Dr. Zheng was Associate Principal Scientist at Schering-Plough Research Institute. Dr. Zheng earned his Ph.D. at Universite de Claude-Bernard Lyon in France and his M.S. degree from Xiamen University in China.
Shu-hui Chen, Ph.D. has been appointed Associate Director of Chemistry. Most recently, Dr. Chen was Group Leader, Chemistry at Vion. Prior to joining Vion, Dr. Chen was Senior Research Scientist at Bristol-Myers Squibb. He received his Ph.D. from Yale University School of Medicine and his B.S. from Fudan University in China.
Edwina Casey hs been promoted to the position of Associate Director of Operations at Vion. Previously at Vion, Ms. Casey was Operations Manager, a position she held since October 1995. Ms. Casey was Vice President of Sales and Marketing for P.J. Murphy Moving & Storage before joining Vion.
Vion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing novel products and technologies for the treatment of cancer and viral diseases. The Company has focused its research efforts in five principal areas: hypoxic cancer cell therapeutics, TAPET cancer therapy, alkylating agent prodrugs, ribonucleotide reductase inhibitors and nucleoside analos. Vion's lead anti-cancer agent Promycin(TM) (porfiromycin) is currently in Phase III clinical trials. For additional information on Vion and its research and product development programs, visit the Company's Internet web site at vionpharm.com.
SOURCE: Vion Pharmaceuticals, Inc. |
